According to a recent LinkedIn post from Aignostics, the company is offering free access to OpenTME, an open-access dataset based on thousands of The Cancer Genome Atlas whole-slide images. The dataset is described as having been processed with the firm’s Atlas H&E-TME platform to provide pre-computed spatial readouts such as tissue quality control, tissue segmentation, cell classification, and neighborhood analysis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that access to OpenTME includes TME Studio, a set of interactive Marimo notebooks designed to support data analysis workflows. For investors, this move suggests a strategy to deepen engagement with academic and industry researchers, potentially accelerating validation of Aignostics’ technology, stimulating ecosystem adoption, and over time enhancing the company’s positioning in digital pathology and spatial biology markets.